Genitourinary Partnering Global Database 2010 to 2022 - Financial Deal Terms for Headline, Upfront and Royalty by Stage of Development
Dublin, June 21, 2022 (GLOBE NEWSWIRE) -- The "Global Genitourinary Partnering 2010-2022: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.
This report provides the full collection of Genitourinary disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.
Trends in Genitourinary partnering deals
Financial deal terms for headline, upfront and royalty by stage of development
Genitourinary partnering agreement structure
Genitourinary partnering contract documents
Top Genitourinary deals by value
Most active Genitourinary dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Genitourinary disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Genitourinary deals.
The report presents financial deal terms values for Genitourinary deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
Report scope
Global Genitourinary Partnering 2010 to 2022 is intended to provide the reader with an in-depth understanding and access to Genitourinary trends and structure of deals entered into by leading companies worldwide.
Global Genitourinary Partnering 2010 to 2022 includes:
Trends in Genitourinary dealmaking in the biopharma industry since 2010
Access to headline, upfront, milestone and royalty data
Access to hundreds of Genitourinary deal contract documents
Comprehensive access to over 680 Genitourinary deal records
The leading Genitourinary deals by value since 2010
Most active Genitourinary dealmakers since 2010
The report includes deals for the following indications: Discharge, Frequency, Incontinence, Itching, Nocturia, Urgency, Acute kidney injury, Amyloidosis, Chronic kidney disease (CKD), Cystitis, Diabetic nephropathy, Dialysis, Hemolytic-uremic syndrome (HUS), Kidney stones, Nephrotic syndrom, Overactive bladder, Peyronie's disease, Polycystic kidney disease, Prostate diseases, Prostatitis, Prostate enlargement, Renal failure, Renal infections, Nephritis, Glomerulonephritis, Pyelonephritis, Vesicoureteral reflux, Urinary tract infection (UTI), plus other genitourinary indications.
In Global Genitourinary Partnering 2010 to 2022, available deals and contracts are listed by:
Headline value
Upfront payment value
Royalty rate value
Stage of development at signing
Deal component type
Technology type
Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Genitourinary Partnering 2010 to 2022 report provides comprehensive access to available deals and contract documents for over 570 Genitourinary deals. Analyzing actual contract agreements allows assessment of the following:
What are the precise Genitourinary rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Key Topics Covered:
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in Genitourinary dealmaking
2.1. Introduction
2.2. Genitourinary partnering over the years
2.3. Genitourinary partnering by deal type
2.4. Genitourinary partnering by industry sector
2.5. Genitourinary partnering by stage of development
2.6. Genitourinary partnering by technology type
2.7. Genitourinary partnering by therapeutic indication
Chapter 3 -Financial deal terms for Genitourinary partnering
3.1. Introduction
3.2. Disclosed financials terms for Genitourinary partnering
3.3. Genitourinary partnering headline values
3.4. Genitourinary deal upfront payments
3.5. Genitourinary deal milestone payments
3.6. Genitourinary royalty rates
Chapter 4 - Leading Genitourinary deals and dealmakers
4.1. Introduction
4.2. Most active in Genitourinary partnering
4.3. List of most active dealmakers in Genitourinary
4.4. Top Genitourinary deals by value
Chapter 5 - Genitourinary contract document directory
5.1. Introduction
5.2. Genitourinary partnering deals where contract document available
Chapter 6 - Genitourinary dealmaking by therapeutic target
6.1. Introduction
6.2. Deals by Genitourinary therapeutic target
Companies Mentioned
3SBio
4D Science
180 Medical
A1M Pharma
AbbeyMoor Medical
Abbott Laboratories
Abbvie
Acer Therapeutics
Acerus
Aceso Life Science
Aceto Corporation
Acino Pharma
ACIST Medical Systems
Acon Labs
Actient Pharmaceuticals
Action Pharma
ActivStyle
Acurx Pharmaceuticals
AdaptHealth
Aduro BioTech
Advanced Uro-Solutions
Advanz Pharma
Advicenne
AEterna Zentaris
Aethlon Medical
Aetna
Affymax
AirStrip Technologies
Akcea Therapeutics
Akebia Therapeutics
AKESOgen
Alavita Pharmaceuticals
AlCana Technologies
Alcavis HDC
Alere Health
Algernon Pharmaceuticals
Alio Medical
AliveCor
Alivio Therapeutics
Allecra Therapeutics
Allegis Pharmaceuticals
Allena Pharmaceuticals
Allergan
Allium Medical Solutions
Alnylam Pharmaceuticals
Altasciences
Altavant Sciences
Althea Technologies
AltheRx
AM-Pharma
Amag Pharmaceuticals
Ambu
American Access Care
American Diabetes Association
American Lung Association
American Medical Systems
American Renal Associates
American Urological Association
Amerigen Pharmaceuticals
Amerinet
AmerisourceBergen
Amgen
AmorChem
Ampio Pharmaceuticals
Amplity Health
Anakuria Therapeutics
ANDROMEDA Medizinische Systems
Angelini Pharma
Angion Biomedica
Angiotech Pharmaceuticals
ANI Pharmaceuticals
Antares Pharma
Anteris Bio
Anthem
Anthem Bluecross
Anthera Pharmaceuticals
AorTech
Apax Partners
Apellis Pharmaceuticals
Apocell
Apollo Hospitals Group
Applied Medical
Aquestive Therapeutics
Aquinox Pharmaceuticals
Arch Biopartners
Archimedes Pharma
Ardelyx
Arena Pharmaceuticals
Argon Medical Devices
Argutus Medical
Arizona State University
Arkray USA
Arrevus
Arriani Pharmaceuticals
Asahi Kasei
Ascend Clinical
Ascend Therapeutics
ASC Therapeutics
ASD Speciality Healthcare
Asia Renal Care
ASKA Pharmaceuticals
Aspect Biosystems
Assembly Biosciences
Astellas Pharma
Astellas Pharma US
AstraZeneca
Astute Medical
Atara Biotherapeutics
Atlantic Dialysis Management Services
Aurinia Pharmaceuticals
Auven Therapeutics
Auxilium Pharmaceuticals
Avanti Specialty Pharmacy Management
Avenu Medical
AWAK Technologies
Axonics Modulation Technologies
Ayogo Health
Aytu BioPharma
Aziyo Biologics
Balboa Nephrology Medical Group
Bausch & Lomb
Baxter International
Baylor Health Care System
B Braun
Beacon Discovery
Beckman Coulter
Becton Dickinson
Beijing King Health
Beijing Leadman Biochemistry
Bellco Health Care
Bellus Health
BenevolentAI
Beth Israel Deaconess Medical Center
Biim Ultrasound
Bio-Techne
BIOASTER
BioCad Holding
Biocon
BioDerm
BioLink Life Sciences
Biomedical Advanced Research and Development Authority
Biomerica
bioMerieux
BioPorto
BioSerenity
Biostar Pharmaceuticals
BioVectra
BK Medical
Blackstone
Bladder Health Network
Blue Cross Blue Shield Association
Boehringer Ingelheim
Boston Scientific
Bridge Medicines
For more information about this report visit https://www.researchandmarkets.com/r/kehchy
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900